Integral Derivatives’s AstraZeneca AZN Stock Holding History

Integral Derivatives’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-4,548	Closed	-$265K	–	1157
2016 Q4	$248K	Buy	+4,548	New	+$258K	﹤0.01%	942
2015 Q1	–	Sell	-21,943	Closed	-$1.52M	–	1089
2014 Q4	$1.54M	Buy	21,943 +383	+2%	+$27.4K	0.03%	525
2014 Q3	$1.54M	Sell	21,560 -2,218	-9%	-$162K	0.03%	563
2014 Q2	$1.77M	Buy	+23,778	New	+$1.72M	0.03%	477
2014 Q1	–	Sell	-7,331	Closed	-$473K	–	1306
2013 Q4	$435K	Buy	+7,331	New	+$398K	0.01%	1089

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Integral Derivatives's AZN Position: Q1 2017 in Review

Integral Derivatives sold out of AstraZeneca (AZN) in Q1 2017, closing a stake of 4,548 shares — an estimated $265K sold.

Integral Derivatives first reported a position in AZN in Q4 2013 and held it in 5 quarters. The position peaked at $1.77M in Q2 2014. 461 funds tracked by Wall St. Rank hold AZN as of Q1 2017.

Integral Derivatives reported no remaining AstraZeneca position as of Q1 2017 after selling out during the quarter.
Integral Derivatives sold 4,548 AstraZeneca shares in Q1 2017, an estimated $265K.
Integral Derivatives first reported a position in AstraZeneca in Q4 2013 and held it in 5 quarters.
Integral Derivatives's AstraZeneca position peaked at $1.77M in Q2 2014.
461 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2017.

Based on Integral Derivatives's 13F filing for Q1 2017, filed 15 May 2017.